Kurt Jetta, CEO of the Tabs Group, an analytics firm that recently completed its seventh annual study of the vitamin business, sees an "overall lethargy" in the business this year that he attributes to the negative effects from the studies. Mr. Jetta still projects overall growth of 3% to 4% for 2014 in a business he pegs at $11.4 billion in all channels, though he's leaning more toward low end of that range, well below high-single or even double-digit growth rates in years past.
Read full article on AdAge
